ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for discussion 같은 생각을 가진 투자자들과 토론할 수 있는 활발한 포럼에서 상호 작용하려면 등록하세요.

IMMP Immutep Ltd

2.69
0.09 (3.46%)
시간외 거래
최종 업데이트: 06:44:39
15분 지연
기업명 주식 심볼 시장 주식 타입
Immutep Ltd IMMP 나스닥 주식예탁증서 (DR)
  가격 변동 가격 변동 % 주식 가격 최근 거래 시간
0.09 3.46% 2.69 06:44:39
개장가 저가 고가 종가 전일 종가
2.73 2.60 2.74 2.69 2.60
시세 정보 더보기 »

최근 뉴스

일자 시간 출처 제목
02/05/202421:00GLOBEPositive Initial Clinical Data Reported from Immutep’s Efti..
29/04/202421:00GLOBEImmutep Quarterly Activities Report Q3 FY24
24/04/202421:00GLOBEImmutep Announces Positive Preliminary Topline Results from..
18/04/202421:00GLOBEImmutep Appoints Leading Research Institute to Conduct..
17/04/202421:00GLOBEImmutep Receives Positive Feedback from the Spanish..
05/03/202422:00GLOBEImmutep Announces First Clinical Data from 90mg Dosing of..
31/01/202406:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
30/01/202422:00GLOBEImmutep Quarterly Activities Report Q2 FY24
04/01/202422:00GLOBEFirst Patient Dosed in Trial Evaluating Efti and the..
21/12/202322:00GLOBEImmutep Receives Constructive Regulatory Feedback on..
21/12/202320:06EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
07/12/202322:00GLOBEImmutep Receives A$2.6 million R&D Tax Incentive from French..
22/11/202322:00GLOBEImmutep Announces Site Expansion for INSIGHT-003 Phase I..
09/11/202322:00GLOBEImmutep Completes Enrollment in TACTI-003 Phase IIb Trial of..
06/11/202322:00GLOBEImmutep Announces Completion of the Safety Lead-In and..
04/11/202301:00GLOBEImmutep Announces New Biomarker Data from TACTI-002 Phase II..
03/11/202319:06EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
02/11/202321:00GLOBEImmutep to Participate in November Investor Events
31/10/202321:00GLOBEImmutep Quarterly Activities Report Q1 FY24
25/10/202321:00GLOBEImmutep receives ~A$1.13 million R&D Tax Incentive
25/10/202319:07EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
24/10/202321:00GLOBEImmutep Reports Promising Clinical Data from INSIGHT-003..
24/10/202319:35EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
23/10/202321:00GLOBEImmutep’s Efti in Combination with KEYTRUDA® Generates..
16/10/202321:00GLOBEImmutep Announces Publication of Abstracts at ESMO Congress..
03/10/202321:00GLOBEImmutep Announces Abstract Accepted for Presentation at the..
21/09/202321:00GLOBECommercial Manufacturing of Eftilagimod Alpha at 2000L Scale..
05/09/202322:00GLOBEImmutep to Participate in September Investor Conferences
01/08/202321:00GLOBEImmutep Receives Positive Scientific Advice from European..
31/07/202321:00GLOBEImmutep Quarterly Activities Report Q4 FY23
28/07/202321:00GLOBEFirst Patient Dosed in Chemotherapy-Free Triple Combination..
28/07/202319:31EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
27/06/202321:00GLOBEImmutep Completes A$80 Million Capital Raise
20/06/202321:00GLOBEImmutep Granted United States Patent for IMP761, a..
07/06/202321:00GLOBEImmutep to Participate at the Jefferies Healthcare..
05/06/202321:00GLOBEImmutep Reports Final Positive Data in 2nd Line Head and..
02/06/202321:00GLOBEImmutep Successfully Completes Institutional Placement and..
29/05/202321:00GLOBEImmutep Selects Charles River Laboratories for IMP761’s GLP..
26/05/202321:00GLOBEImmutep Announces Publication of Abstracts for ASCO 2023..
25/05/202321:00GLOBEImmutep Doses First Patient in AIPAC-003 Phase II/III Trial..
24/05/202321:00GLOBEImmutep Announces Promising New Clinical Data from Triple..
17/05/202321:00GLOBEImmutep’s Efti in Combination with Pembrolizumab Achieves..
16/05/202321:00GLOBEImmutep Receives Positive Feedback from FDA on Late-Stage..
09/05/202321:00GLOBEImmutep to Participate in the JMP Securities Life Sciences..

최근 히스토리

Delayed Upgrade Clock